| Identification | Back Directory | [Name]
(+/-)-N-3-Benzylnirvanol | [CAS]
93879-40-4 | [Synonyms]
(+/-)-N-3-Benzylnirvanol
3-Benzyl-5-ethyl-5-phenyl-hydantoi
3-Benzyl-5-ethyl-5-phenyl-hydantoin
5-Ethyl-5-phenyl-3-(phenylmethyl)-2,4-imidazolidinedione | [Molecular Formula]
C18H18N2O2 | [MDL Number]
MFCD07353973 | [MOL File]
93879-40-4.mol | [Molecular Weight]
294.35 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
134-136°C | [density ]
1.190±0.06 g/cm3(Predicted) | [storage temp. ]
-20?C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
8.02±0.70(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
It is a potent and selective human CYP2C19 inhibitor | [Description]
(±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-benzylnirvanol and (–)-N-3-benzylnirvanol. (+)-N-3-benzylnirvanol and (–)-N-3-benzylnirvanol are inhibitors of the cytochrome P450 (CYP) isoform CYP2C19 (Kis = 0.25 and 5.3 μM, respectively). (±)-N-3-Benzylnirvanol (20 mg/kg, i.p.) lowers plasma levels of cholesterol in mice. | [References]
[1] HISASHI SUZUKI. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.[J]. Drug Metabolism and Disposition, 2002, 23 1: 235-239. DOI: 10.1124/dmd.30.3.235
[2] JAMES H. MAGUIRE Iris H H Akula R Murthy. Hypolipidemic activity of antiepileptic 5-phenylhydantoins in mice[J]. European journal of pharmacology, 1985, 117 1: Pages 135-138. DOI: 10.1016/0014-2999(85)90483-2 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|